Abstract 5845
Background
Subsequent treatment with ipi offers 10-13% ORR (Bowyer 2016, Long 2016) in aPD1 refractory MM. Tilsotolimod, a synthetic TLR9 agonist oligonucleotide, acts on macrophages and dendritic cells to alter the tumor microenvironment. Local drug-induced type 1 interferon response results in increased antigen presentation and downstream T cell activation and proliferation in injected and non-injected lesions (Haymaker, SITC 2017).
Methods
The study will enroll up to 60 pts with rMM to receive IT (with/without IG) tilsotolimod (scheduled weeks 1,2,3,5,8,11,17, 23 and 29); ipi is given per the product label starting at week 2. Pts with M1c disease, mucosal melanoma and BRAF mutations were included. The primary endpoint is RECIST1.1 objective response rate (ORR); other endpoints are safety and tolerability and disease control rate (DCR). Immune analyses of T-cell repertoire diversity evaluated by high-throughput CDR3 sequencing. Phase 2 accrual is ongoing.
Results
As of 9 Apr 2018, 26 pts have been treated with tilsotolimod 8mg+ ipi, including 5 pts who received IG injections to deep visceral lesions or lymph nodes. Median age: 65.8 (range 39-91 yrs); 11 IVM1c. 6 pts had irAEs [hypophysitis (2), hepatitis (2), adrenal insufficiency (1), Guillain-Barre syndrome (1), colitis (1), enterocolitis (1)], which responded to standard measures. Injection-related toxicities were grade 1-2 transient fever and flu like symptoms lasting <48 hours. Major expanding T-cell clones are found to be shared in responding local and distant lesions indicating that reactivation is to a shared antigen in responding patients. As of 9 May 2018, 21 pts were assessed for response: 38% ORR and 71% DCR (2 CR, 6 PR, 7 SD). 6 of 8 responses are ongoing including 1 CR > 23 mo. 10 pts had BRAF mutations (1 CR, 3 PR, and 4 SD).
Conclusions
IT tilsotolimod 8mg+ ipi is well tolerated and shows substantial clinical benefit and durable responses. The ORR of 38% compares favorably to ipi in this challenging population, leading to an ongoing global randomized Phase 3 study of tilsotolimod 8mg+ipi vs. ipi in aPD-1 rMM.
Clinical trial identification
NCT02644967.
Legal entity responsible for the study
Idera Pharmaceuticals.
Funding
Idera Pharmaceuticals.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3745 - Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
Presenter: Georgina Long
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Abstract
2134 - Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: evidence for systemic effects in a phase 2, single-arm study
Presenter: Helen Gogas
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Abstract
4894 - Phase 2 Study Comparing Pembrolizumab (PEM) with Intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra).
Presenter: Elisa Rozeman
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Abstract
Poster Discussion session - Melanoma and other skin tumours - Invited Discussant LBA45, 1245PD, 1246PD and LBA46
Presenter: Susana Puig Sarda
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Slides
Webcast
4311 - Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
Presenter: Celeste Lebbé
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Abstract
3540 - Phase II multicenter, single arm, open label study of Nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma. GEM1402.NCT02626962
Presenter: Josep Maria Piulats Rodriguez
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Abstract
Poster Discussion session - Melanoma and other skin tumours - Invited Discussant LBA47 and 1247PD
Presenter: Georgina Long
Session: Poster Discussion session - Melanoma and other skin tumours
5352 - Efficacy of Pembrolizumab (Pembro) in Patients (Pts) With Advanced Melanoma with Stable Brain Metastases (BM) at Baseline: A Pooled Retrospective Analysis
Presenter: Omid Hamid
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Abstract
1733 - Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase.
Presenter: Clara Allayous
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Abstract
Poster Discussion session - Melanoma and other skin tumours - Invited Discussant 1248PD and 1249PD
Presenter: Jean Jacques Grob
Session: Poster Discussion session - Melanoma and other skin tumours
Resources:
Slides
Webcast